AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

11:38am EDT
Price Change (% chg)

43.50p (+0.97%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for AZN.L


AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)


Beta: 0.39
Market Cap (Mil.): £56,740.66
Shares Outstanding (Mil.): 1,262.72
Dividend: 53.10
Yield (%): 3.78


  AZN.L Industry Sector
P/E (TTM): 45.55 32.66 33.47
EPS (TTM): 0.99 -- --
ROI: 5.03 18.15 17.39
ROE: 8.94 18.86 18.25
Search Stocks

Wall St. climbs as expectations shift on Fed policy

NEW YORK - U.S. stocks rose on Tuesday and the S&P notched its best performance in a month after a report shifted investor expectations for the Federal Reserve's policy statement due on Wednesday.

16 Sep 2014

FDA approves AstraZeneca, Nektar constipation drug

- The U.S. Food and Drug Administration approved an oral therapy to treat opioid-induced constipation developed by Nektar Therapeutics and AstraZeneca Plc.

16 Sep 2014

CORRECTED-FDA approves AstraZeneca, Nektar constipation drug

Sept 16 - The U.S. Food and Drug Administration approved an oral therapy to treat opioid-induced constipation developed by Nektar Therapeutics and AstraZeneca Plc .

16 Sep 2014

Wall Street to open lower, eyes on Fed meeting

NEW YORK - U.S. stocks were set to open lower on Tuesday with traders positioning for a Federal Reserve meeting expected to provide clues on the short term direction of U.S. interest rates.

16 Sep 2014

GM's Opel to cut Russia production as slowdown bites

BERLIN - Opel Group, the European arm of General Motors , is cutting production and shedding around 500 jobs in Russia, hit by the weak Russian rouble and a plunge in local demand due to a slowing economy and Western sanctions.

16 Sep 2014

AstraZeneca gets up to $500 million from Lilly for Alzheimer's drug

LONDON - AstraZeneca has signed a partnership deal with U.S. rival Eli Lilly that could earn the British company up to $500 million if a promising – but risky – experimental Alzheimer’s drug proves successful.

16 Sep 2014

UPDATE 1-AstraZeneca gets up to $500 mln from Lilly for Alzheimer's drug

* Full payout of up to $500 mln dependent on drug's success

16 Sep 2014

AstraZeneca to partner with Eli Lilly on Alzheimer's drug

LONDON, Sept 16 - AstraZeneca has struck a partnership deal worth up to $500 million with Eli Lilly for the British group's experimental Alzheimer's drug, which is set to enter late-stage Phase III development.

16 Sep 2014

BRIEF-AstraZeneca to develop Alzheimer's drug with Eli Lilly

* Lilly will pay AstraZeneca up to $500 million in development and regulatory milestone payments

16 Sep 2014

UPDATE 1-Cost a focus as GSK takes lead in new wave of biotech lung drugs

* GSK drug ahead of similar ones from Teva and AstraZeneca

08 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: ValuEngine, Inc.
Provider: S&P Capital IQ – STARS Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks